ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0833

Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics

Andrea De Diego Sola1, César Antonio Egües Dubuc2, Nerea Alcorta Lorenzo1, Jesús Alejandro Valero Jaimes2, Olga Maíz Alonso3, Luis Maria Lopez Dominguez1, Esther Uriarte Isacelaya4, Jorge Cancio Fanlo5, María Asunción Aranguren Redondo6, María Belén Irastorza Larburu7 and Joaquín María Belzunegui Otano3, 1Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Pais Vasco, Spain, 2Hospital Universitario Donostia, San Sebastián, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Universitario Donostia, San Sebastian, Spain, 5Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 6Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 7Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastián, Spain

Meeting: ACR Convergence 2020

Keywords: Anti-TNF Drugs, biologic response modifiers, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The emergence of biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA) (“treat-to-treat” strategy).  Once sustained remission is achieved, optimized treatment of bDMARD (OT) is considered: using drugs at lower doses than indicated in data sheets. Studies show that 33-64.2% of patients on OT lose remission in the first 6 months. Still, it is a feasible practice in selected patients and so, it is of interest to study the situation of optimized patients to improve our practice. Our objectives were to describe demographic, clinical, analytical and therapeutic characteristics of RA patients on OT in our hospital. Secondly, to study the survival of OT and to compare patients with survival longer or shorter to one year.

Methods: We did a retrospective review of the medical records of RA patients who began bDMARD OT [Abatacept (ABA), anti-TNF drugs and Tocilizumab (TCZ)] between January 2014 and December 2018. We defined the end of OT as the restart of the usual dose. Continuous variables are described with mean and standard deviation (SD) and qualitative variables are shown in absolute value and percentage. We divided the sample into patients with OT survival greater than or equal to one year and patients with OT survival less than one year, after which the characteristics of both populations were compared. Categorical variables were analyzed using Pearsons chi2 and quantitative variables using Student’s t-test. Survival analysis was performed using a Kaplan-Meier estimator.

Results: We identified 234 RA patients on bDMARD at our hospital, of which 53 (22.6%) had been optimized between January 2014 and December 2018: 39 (73.6%) with anti-TNF, 7 (13.2) with ABA and 7 (13.2%) with TCZ. Their characteristics are shown in table 1. It is worth mentioning the rate of monotherapy (43.3%) and the low number of bDMARD prior to optimization (median 0.71, SD 0.97). The median survival of OT was 33.8 months (Image 1) and thirty-nine patients (73.6%) maintained OT for at least one year (95% confidence interval, 0.59 to 0.83). When comparing patients with survival greater/equal versus shorter to one year (table 2), the only variable showing significant differences was the presence of erosions at beginning of OT (28 patients in the >1 year group vs 7 in the < 1 year group; p=0.012). Although the difference is not significant (p = 0.07), patients with a survival of less than one year have more time between the debut and the beginning of the first conventional synthetic DMARD (csDMARD).

Conclusion: Two limitations should be noted: the sample size and the lack of a homogeneous optimization schedule among rheumatologists. More studies are needed to define the characteristics of patients who can safely benefit from OT.

Time is expressed in months.

ACPA: anti-citrullinated protein antibodies; mRF: monoclonal rheumatoid factor; Erosions: presence of erosions at Optimization; bDMARD: biological DMARD; ETN: Etanercept; ADA: Adalimumab; ABA: Abatacept; TCZ: Tocilizumab; GOL: Golimumab; CERT: Certolizumab; Opt bDMARD: bDMARD optimized; csDMARD: conventional synthetic DMARD; Low activity: DAS28 < 3.2


Disclosure: A. De Diego Sola, None; C. Egües Dubuc, None; N. Alcorta Lorenzo, None; J. Valero Jaimes, None; O. Maíz Alonso, None; L. Lopez Dominguez, MSD, Pfizer, Lilly, Gebro Pharma, 1; E. Uriarte Isacelaya, None; J. Cancio Fanlo, None; M. Aranguren Redondo, None; M. Irastorza Larburu, None; J. Belzunegui Otano, None.

To cite this abstract in AMA style:

De Diego Sola A, Egües Dubuc C, Alcorta Lorenzo N, Valero Jaimes J, Maíz Alonso O, Lopez Dominguez L, Uriarte Isacelaya E, Cancio Fanlo J, Aranguren Redondo M, Irastorza Larburu M, Belzunegui Otano J. Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/optimized-treatment-of-biological-disease-modifying-drugs-in-routine-clinical-practice-survival-study-and-analysis-of-patient-characteristics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimized-treatment-of-biological-disease-modifying-drugs-in-routine-clinical-practice-survival-study-and-analysis-of-patient-characteristics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology